Orchid's strong NDD pipeline encompasses high-growth therapeutic segments like anti-diabetic, oncology among others. Orchid’s multi-therapeutic, multi-lead portfolio and selective partnerships with global customers for R&D projects reflects its emergence in the global drug discovery space as a potential player. Orchid’s R&D stands out in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation, with faster decision making and execution excellence, re-enforcing its position as a preferred partner.

The infrastructure comprises of independent laboratories for medicinal chemistry, analytical chemistry, molecular modeling, pharmacology & pharmacokinetics and molecular biology. Lead molecules have been identified in two therapeutic areas – anti-infectives and pain management – based on confirmatory microbiological and pharmacological studies. Pre-formulation and other studies are also in progress for further lead optimisation. Furthermore, our medicinal chemistry division has well trained scientists who perform design and synthesis of novel molecules in various therapeutic areas such as anti-infectives, anti-inflammatory, anti-cancer and metabolic disorders. They interact with the drug design group to synthesise second-generation patentable molecules that are either inspired by natural products or successfully marketed in these therapeutic areas.